Santa Clara, CA-August 27, 2009
NewCardio, Inc., a cardiac diagnostic and services company, announced that a top-three contract research organization has signed a Master Services Agreement (MSA) to use the company's QTinno software suite as its technology in fully automated Thorough QT (TQT) and Phase 1 studies delivered by its centralized ECG core lab.
NewCardio expects to collaborate on the first fully automated study, tentatively scheduled to begin during the third quarter of 2009.
NewCardio’s innovative 3D ECG platform technology is intended to improve the accuracy and increase the diagnostic value of the standard 12-lead electrocardiogram (ECG). QTinno is a software suite that provides an automated analysis of QT intervals and other ECG-based cardiac safety for the pharmaceutical industry and drug regulators.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.